← Every company
Agios Pharmaceuticals Inc Patents
What Agios Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
AGIO on carbonthat →Filings on file
40
Granted
0
Still pending
40
Filed under
3 names
40 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS OF USING PYRUVATE KINASE ACTIVATORSA61K 31/496, A61P 7/06Filed as Agios Pharmaceuticals, Inc.2026-04-17Samuel V. Agresta | pending |
| CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDEC07D 215/36, C07D 401/12, A61P 7/06, A61P 7/00, A61P 13/00, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 31/496, C07B2200/13Filed as Agios Pharmaceuticals, Inc.2026-03-26Jose Luis Rios Lizarraga | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2026-03-04LUCREZIA DE PASCALIS | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2026-03-04LUCREZIA DE PASCALIS | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSC07D 519/00, A61P 25/18, A61K 31/497, C07B 59/002Filed as Agios Pharmaceuticals, Inc.2026-03-04Lucrezia De Pascalis | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2026-03-04LUCREZIA DE PASCALIS | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2026-03-04LUCREZIA DE PASCALIS | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2026-03-04LUCREZIA DE PASCALIS | pending |
| SYNTHESIS OF PYRUVATE KINASE ACTIVATORSFiled as AGIOS PHARMACEUTICALS, INC.2026-02-18KRISTOPHER M. DEPEW | pending |
| SYNTHESIS OF PYRUVATE KINASE ACTIVATORSFiled as Agios Pharmaceuticals, Inc.2026-01-02Daniel R. Fandrick | pending |
| CRYSTALLINE SALTS OR AMORPHOUS FORMS OF 2-((1H-PYRAZOL-3-YL)METHYL)-6-((6-AMINOPYRIDIN-2-YL)METHYL)-4-METHYL-4,6-DIHYDRO -5H-THIAZOLO[5',4':4,5]PYRROLO[2,3-D]PYRIDAZIN-5-ONEA61K 31/5025, A61K 9/2027, A61K 9/2054, C07C 59/255, C07D 513/14Filed as Agios Pharmaceuticals, Inc.2025-11-13Daniel R. Fandrick | pending |
| BCAT2 INHIBITORSA01K 67/0275, C12N2310/20, A61P 3/00, C12N 9/226, A01K2217/075, A01K2217/15, A01K2227/105, A01K2267/0306, A61K 31/4196, A61K 31/444, C07D 401/14, C07D 403/14, C07D 471/04, C12N 15/113Filed as Agios Pharmaceuticals, Inc.2025-11-12Barden Chan | pending |
| USE OF A PYRUVATE KINASE ACTIVATOR IN THE TREATMENT OF RENAL FIBROSIS AND OTHER RENAL DISEASESFiled as AGIOS PHARMACEUTICALS, INC.2025-10-27HUI GAO | pending |
| METHODS OF USING PYRUVATE KINASE ACTIVATORSA61K 31/496, A61P 7/06Filed as Agios Pharmaceuticals, Inc.2025-08-21Samuel V. Agresta | pending |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONSA61K 31/497, C07D 215/36, C07D 241/22, Y02P 20/582, A61P 9/10, A61P 9/00, A61P 35/00, A61K 31/5513, C07D 215/40, C07D 239/42, C07D 241/20, C07D 243/08, C07D 271/12, C07D 277/64, C07D 277/68, C07D 295/192, C07D 319/18, C07D 401/12, C07D 401/14, C07D 403/12, C07D 405/12, C07D 407/12, C07D 409/12, C07D 417/12, C07D 417/14Filed as Agios Pharmaceuticals, Inc.2025-08-05Francesco G. Salituro | pending |
| PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPYA61K 31/496, A61P 7/06, A61K 31/415, A61K 31/4406, A61K 31/47, A61K 31/4965, A61K 31/497, A61K 31/535, C07C 13/04, C07C 307/10, C07D 205/04, C07D 213/81, C07D 215/14, C07D 235/06, C07D 241/04, C07D 241/20, C07D 271/12, C07D 295/192, C07D 307/14, C07D 333/24, C07D 401/12, C07D 405/12, C07D 417/12, A61K 31/495, A61P 7/00Filed as Agios Pharmaceuticals, Inc.2025-07-08Shin-San Michael Su | pending |
| USE OF A PK ACTIVATOR IN THE TREATMENT OF SICKLE CELL DISEASEFiled as AGIOS PHARMACEUTICALS, INC.2025-03-25MICHAEL URBAN CALLAGHAN | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as Agios Pharmaceuticals, Inc.2025-03-05Lucrezia De Pascalis | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as Agios Pharmaceuticals, Inc.2025-03-05Lucrezia De Pascalis | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as Agios Pharmaceuticals, Inc.2025-03-05Lucrezia De Pascalis | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as Agios Pharmaceuticals, Inc.2025-03-05Lucrezia De Pascalis | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as Agios Pharmaceuticals, Inc.2025-03-05Lucrezia De Pascalis | pending |
| SYNTHESIS OF PYRUVATE KINASE ACTIVATORSFiled as Agios Pharmaceuticals, Inc.2025-02-18Kristopher M. Depew | pending |
| USE OF A PYRUVATE KINASE ACTIVATOR IN THE TREATMENT OF RENAL FIBROSIS AND OTHER RENAL DISEASESFiled as Agios Pharmaceuticals, Inc.2024-10-28Hui Gao | pending |
| MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450A61K 38/45, A61K 45/06, C12Y 207/0104Filed as Agios Pharmaceuticals, Inc.2024-10-16Chandra Agarwal Prakash | pending |
| PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERSA61K 31/5025, C07D 513/14, A61P 7/06, A61P 3/10, A61P 7/08, A61P 35/00, A61K 31/506, A61K 31/519, A61K 45/06, C07D 241/36Filed as Agios Pharmaceuticals, Inc.2024-09-12Giovanni CIANCHETTA | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2024-08-29LUCREZIA DE PASCALIS | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSFiled as AGIOS PHARMACEUTICALS, INC.2024-08-29LUCREZIA DE PASCALIS | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSA61K 31/444, C07D 471/04, C07D 519/00, A61P 25/14, A61P 3/00, A61P 25/00, A61K 31/497, A61K 31/501, A61K 31/506, A61K 31/5377Filed as Agios Pharmaceuticals, Inc.2024-08-29Lucrezia De Pascalis | pending |
| (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIAC07D 471/04, A61K 31/423, A61K 31/437, A61K 31/438, A61K 31/4439, A61K 31/444, A61K 31/4545, A61K 31/496, A61K 31/497, A61K 31/506, A61K 31/5377, C07D 487/04, C07D 519/00, A61P 25/00, A61K 31/55, A61K 45/06Filed as Agios Pharmaceuticals,Inc.2024-08-26Lucrezia De Pascalis | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSC07D 471/04, A61K 31/437, A61K 31/444, A61K 31/4545, A61K 31/496, A61K 31/506, A61K 31/5377, A61K 31/55, A61K 45/06, C07D 487/04, C07D 519/00, A61P 25/00, A61K 31/423, A61K 31/438, A61K 31/4439, A61K 31/497Filed as Agios Pharmaceuticals, Inc.2024-08-26Sandra King | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSA61P 25/00, C07D 471/04, C07D 519/00, A61P 3/00, A61K 31/437, A61K 31/4709, A61K 31/4725, A61K 31/496, A61K 31/502, A61K 31/506, A61K 31/517Filed as Agios Pharmaceuticals, Inc.2024-08-26Sandra King | pending |
| COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSC07D 471/04, A61P 3/00, A61K 31/437, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/496, A61K 31/497, A61K 31/5025, A61K 31/506, A61K 31/5377, A61K 31/55, A61K 45/06, C07D 487/04, C07D 519/00Filed as Agios Pharmaceuticals, Inc.2024-08-26Sandra King | pending |
| USE OF A PK ACTIVATOR IN THE TREATMENT OF SICKLE CELL DISEASEFiled as Agios Pharmaceuticals, Inc.2024-08-19Michael Urban Callaghan | pending |
| SYNTHESIS OF PYRUVATE KINASE ACTIVATORSFiled as AGIOS PHARMACEUTICALS, INC.2024-07-05DANIEL R. FANDRICK | pending |
| BCAT2 INHIBITORSFiled as AGIOS PHARMACEUTICALS, INC.2024-05-16BARDEN CHAN | pending |
| COMPOUNDS FOR TREATING MDS-ASSOCIATED ANEMIAS AND OTHER CONDITIONSA61K 31/496, A61K 31/5025, A61P 7/06Filed as Agios Pharmaceuticals, Inc.2024-05-16Vanessa Beynon | pending |
| CRYSTALLINE FORMS OF 2-((1H-PYRAZOL-3-YL)METHYL)-6-((6-AMINOPYRIDIN-2-YL)METHYL)-4-METHYL-4,6-DIHYDRO-5H-THIAZOLO[5',4':4,5]PYRROLO[2,3-D]PYRIDAZIN-5-ONEFiled as AGIOS PHARMACEUTICALS, INC.2024-05-15DANIEL R. FANDRICK | pending |
| BCAT2 INHIBITORSC07D 471/04, C07D 473/00, A61P 3/00, A61K 31/427, A61K 31/437, A61K 31/4439, A61K 31/444, A61K 31/454, A61K 31/4545, A61K 31/506, A61K 31/52, A61K 31/5377, C07D 409/14, C07D 413/14, C07D 417/14, C07D 473/32Filed as AGIOS PHARMACEUTICALS, INC.2024-05-10Claude Barberis | pending |
| USE OF A PK ACTIVATOR IN THE TREATMENT OF SICKLE CELL DISEASEFiled as Agios Pharmaceuticals, Inc.2024-03-27Michael Urban Callaghan | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on AGIO
Company overviewEverything on AGIO in one place, with the price.SEC filingsWhat AGIO's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AGIO's own officers and directors buy and sell.Who owns itEvery manager reporting a position in AGIO.Funds holding itWhich funds and ETFs hold AGIO, and how big a bet.LobbyingWhat AGIO spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on AGIO's account, and who they worked for.Federal contractsWhat federal agencies pay AGIO.